December 21, 2017 / 6:20 PM / 6 months ago

BRIEF-Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta

Dec 21 (Reuters) - Pfizer Inc:

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA

* PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below